Related Experiment Video

Updated: Jul 13, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Mapping ErbB receptors on breast cancer cell membranes during signal transduction

Shujie Yang1, Mary Ann Raymond-Stintz, Wenxia Ying

  • 1Department of Pathology and Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NM 87131, USA.

Journal of Cell Science
|July 27, 2007
PubMed

Insights

This study maps ErbB receptor distributions in breast cancer cells, revealing how receptor clustering and docking proteins influence signaling pathways. Understanding these interactions is key for targeted cancer therapies.

Area of Science:

  • Cell biology
  • Molecular oncology
  • Cancer research

Background:

  • ErbB receptors (ErbB1-4) play critical roles in cell growth and cancer.
  • Aberrant ErbB signaling is a hallmark of many cancers, including breast cancer.
  • SKBR3 cells are a well-established model for studying ErbB receptor biology.

Purpose of the Study:

  • To investigate the spatial distribution and interactions of ErbB receptors (ErbB2, EGFR, ErbB3) on SKBR3 breast cancer cells.
  • To elucidate the role of receptor clustering and docking proteins in modulating downstream signaling.
  • To understand how different ligands (EGF, Heregulin) affect receptor organization and activity.

Main Methods:

  • Immunoelectron microscopy was employed to visualize and map receptor distributions.
  • Kinase inhibitors were used to assess the impact on ErbB2 phosphorylation and clustering.
  • Analysis of co-clustering with other ErbB receptors and docking proteins (PI 3-kinase, Shc, STAT5).

Main Results:

  • ErbB2 is the most abundant receptor, found phosphorylated and clustered.
  • Kinase inhibitors reduced ErbB2 phosphorylation but not cluster dispersal.
  • EGF treatment showed modest co-clustering of ErbB2 and EGFR, suggesting homointeractions.
  • Heregulin induced dramatic ErbB3 clusters containing ErbB2, EGFR, and PI 3-kinase.
  • Shc levels increased with EGF, while STAT5 phosphorylation was enhanced.

Conclusions:

  • Receptor topography and distinct docking protein associations modulate ErbB signaling.
  • Targeting specific receptor interactions and signaling complexes may offer therapeutic strategies.
  • The spatial organization of ErbB receptors is crucial for their functional output in cancer cells.

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...